GSK vs. REGN, BMY, ZTS, VRTX, SNY, TAK, PFE, ABT, NVS, and AZN
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Sanofi (SNY), Takeda Pharmaceutical (TAK), Pfizer (PFE), Abbott Laboratories (ABT), Novartis (NVS), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.
GSK (NYSE:GSK) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
Regeneron Pharmaceuticals has a consensus target price of $977.77, indicating a potential upside of 10.71%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than GSK.
GSK has higher revenue and earnings than Regeneron Pharmaceuticals. GSK is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Regeneron Pharmaceuticals had 9 more articles in the media than GSK. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 17 mentions for GSK. Regeneron Pharmaceuticals' average media sentiment score of 0.68 beat GSK's score of 0.20 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.
Regeneron Pharmaceuticals has a net margin of 30.14% compared to GSK's net margin of 16.24%. GSK's return on equity of 51.45% beat Regeneron Pharmaceuticals' return on equity.
Regeneron Pharmaceuticals received 678 more outperform votes than GSK when rated by MarketBeat users. Likewise, 66.58% of users gave Regeneron Pharmaceuticals an outperform vote while only 57.04% of users gave GSK an outperform vote.
GSK has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.
15.7% of GSK shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 8.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Regeneron Pharmaceuticals beats GSK on 13 of the 18 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
